479 related articles for article (PubMed ID: 30495978)
1. Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials.
Arbyn M; Xu L
Expert Rev Vaccines; 2018 Dec; 17(12):1085-1091. PubMed ID: 30495978
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial.
Porras C; Tsang SH; Herrero R; Guillén D; Darragh TM; Stoler MH; Hildesheim A; Wagner S; Boland J; Lowy DR; Schiller JT; Schiffman M; Schussler J; Gail MH; Quint W; Ocampo R; Morales J; Rodríguez AC; Hu S; Sampson JN; Kreimer AR;
Lancet Oncol; 2020 Dec; 21(12):1643-1652. PubMed ID: 33271093
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of the AS04-Adjuvanted HPV16/18 Vaccine: Pooled Analysis of the Costa Rica Vaccine and PATRICIA Randomized Controlled Trials.
Tota JE; Struyf F; Sampson JN; Gonzalez P; Ryser M; Herrero R; Schussler J; Karkada N; Rodriguez AC; Folschweiller N; Porras C; Schiffman M; Schiller JT; Quint W; Kreimer AR; Wheeler CM; Hildesheim A;
J Natl Cancer Inst; 2020 Aug; 112(8):818-828. PubMed ID: 31697384
[TBL] [Abstract][Full Text] [Related]
5. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
Lehtinen M; Paavonen J; Wheeler CM; Jaisamrarn U; Garland SM; Castellsagué X; Skinner SR; Apter D; Naud P; Salmerón J; Chow SN; Kitchener H; Teixeira JC; Hedrick J; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; De Carvalho NS; Germar MJ; Peters K; Mindel A; De Sutter P; Bosch FX; David MP; Descamps D; Struyf F; Dubin G;
Lancet Oncol; 2012 Jan; 13(1):89-99. PubMed ID: 22075171
[TBL] [Abstract][Full Text] [Related]
6. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
[TBL] [Abstract][Full Text] [Related]
7. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
Wheeler CM; Castellsagué X; Garland SM; Szarewski A; Paavonen J; Naud P; Salmerón J; Chow SN; Apter D; Kitchener H; Teixeira JC; Skinner SR; Jaisamrarn U; Limson G; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Harper DM; Huh W; Hardt K; Zahaf T; Descamps D; Struyf F; Dubin G; Lehtinen M;
Lancet Oncol; 2012 Jan; 13(1):100-10. PubMed ID: 22075170
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic vaccination against human papillomaviruses to prevent vulval and vaginal cancer and their precursors.
Xu L; Selk A; Garland SM; Bogliatto F; Kyrgiou M; Weyers S; Arbyn M
Expert Rev Vaccines; 2019 Nov; 18(11):1157-1166. PubMed ID: 31718338
[No Abstract] [Full Text] [Related]
9. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women.
Konno R; Yoshikawa H; Okutani M; Quint W; V Suryakiran P; Lin L; Struyf F
Hum Vaccin Immunother; 2014; 10(7):1781-94. PubMed ID: 25424783
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.
Paavonen J; Naud P; Salmerón J; Wheeler CM; Chow SN; Apter D; Kitchener H; Castellsague X; Teixeira JC; Skinner SR; Hedrick J; Jaisamrarn U; Limson G; Garland S; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Jenkins D; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G;
Lancet; 2009 Jul; 374(9686):301-14. PubMed ID: 19586656
[TBL] [Abstract][Full Text] [Related]
11. Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial.
Garland SM; Paavonen J; Jaisamrarn U; Naud P; Salmerón J; Chow SN; Apter D; Castellsagué X; Teixeira JC; Skinner SR; Hedrick J; Limson G; Schwarz TF; Poppe WA; Bosch FX; de Carvalho NS; Germar MJ; Peters K; Del Rosario-Raymundo MR; Catteau G; Descamps D; Struyf F; Lehtinen M; Dubin G;
Int J Cancer; 2016 Dec; 139(12):2812-2826. PubMed ID: 27541373
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.
Skinner SR; Szarewski A; Romanowski B; Garland SM; Lazcano-Ponce E; Salmerón J; Del Rosario-Raymundo MR; Verheijen RH; Quek SC; da Silva DP; Kitchener H; Fong KL; Bouchard C; Money DM; Ilancheran A; Cruickshank ME; Levin MJ; Chatterjee A; Stapleton JT; Martens M; Quint W; David MP; Meric D; Hardt K; Descamps D; Geeraerts B; Struyf F; Dubin G;
Lancet; 2014 Dec; 384(9961):2213-27. PubMed ID: 25189358
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.
Paavonen J; Jenkins D; Bosch FX; Naud P; Salmerón J; Wheeler CM; Chow SN; Apter DL; Kitchener HC; Castellsague X; de Carvalho NS; Skinner SR; Harper DM; Hedrick JA; Jaisamrarn U; Limson GA; Dionne M; Quint W; Spiessens B; Peeters P; Struyf F; Wieting SL; Lehtinen MO; Dubin G;
Lancet; 2007 Jun; 369(9580):2161-2170. PubMed ID: 17602732
[TBL] [Abstract][Full Text] [Related]
14. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
Muñoz N; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; Garcia PJ; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Huh WK; Joura EA; Kurman RJ; Majewski S; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Lupinacci LC; Giacoletti KE; Sings HL; James MK; Hesley TM; Barr E; Haupt RM
J Natl Cancer Inst; 2010 Mar; 102(5):325-39. PubMed ID: 20139221
[TBL] [Abstract][Full Text] [Related]
15. Trends in Human Papillomavirus Vaccine Types 16 and 18 in Cervical Precancers, 2008-2014.
McClung NM; Gargano JW; Bennett NM; Niccolai LM; Abdullah N; Griffin MR; Park IU; Cleveland AA; Querec TD; Unger ER; Markowitz LE;
Cancer Epidemiol Biomarkers Prev; 2019 Mar; 28(3):602-609. PubMed ID: 30792242
[TBL] [Abstract][Full Text] [Related]
16. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions.
Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Dillner J; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Maansson R; Lu S; Vuocolo S; Hesley TM; Saah A; Barr E; Haupt RM
Cancer Prev Res (Phila); 2009 Oct; 2(10):868-78. PubMed ID: 19789295
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.
Apter D; Wheeler CM; Paavonen J; Castellsagué X; Garland SM; Skinner SR; Naud P; Salmerón J; Chow SN; Kitchener HC; Teixeira JC; Jaisamrarn U; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Mindel A; de Sutter P; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G;
Clin Vaccine Immunol; 2015 Apr; 22(4):361-73. PubMed ID: 25651922
[TBL] [Abstract][Full Text] [Related]
18. Impact of HPV-16/18 AS04-adjuvanted vaccine on preventing subsequent infection and disease after excision treatment: post-hoc analysis from a randomized controlled trial.
Zhao S; Hu S; Xu X; Zhang X; Pan Q; Chen F; Zhao F
BMC Infect Dis; 2020 Nov; 20(1):846. PubMed ID: 33198657
[TBL] [Abstract][Full Text] [Related]
19. Roles of extended human papillomavirus genotyping and multiple infections in early detection of cervical precancer and cancer and HPV vaccination.
Song F; Yan P; Huang X; Wang C; Du H; Qu X; Wu R
BMC Cancer; 2022 Jan; 22(1):42. PubMed ID: 34991494
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of prophylactic HPV vaccines against cervical abnormalities and HPV infection in Japan: The J-HERS 2021 multicenter study.
Saeki Y; Saito M; Irie T; Itoh F; Enatsu A; Komura H; Fujii M; Fujii R; Hidaka N; Maehama T; Shirasu N; Waseda T; Shibata T; Takada E; Mibe K; Sakamoto J; Yamada S; Takakura M; Sasagawa T
J Med Virol; 2024 Feb; 96(2):e29413. PubMed ID: 38314927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
